815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Rush Enterprises appointed Jody Pollard as Chief Operating Officer effective March 23, 2026, succeeding Jason Wilder, who has left the company. Pollard has been with the company since 1999 and was Senior Vice President - Truck and Aftermarket Sales from March 2021 until this promotion. The filing says the Compensation Committee will review possible changes to his pay, but no changes have been decided, and the filing contains no financial results.
Jody Pollard, age 49, named COO effective March 23, 2026
Jason Wilder, COO since November 2024, has left the company
Compensation Committee plans to review Pollard's pay; any changes subject to final approval
Pollard will report to W.M. "Rusty" Rush, Chairman, CEO and President
Globus Medical director John A. DeFord, Ph.D., resigned from the Board of Directors effective immediately on March 23, 2026, and said the decision was not a result of any disagreement with the company. He will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. The filing describes a board departure with no change to financial results or guidance.
Resignation effective immediately, announced March 23, 2026
Company states the decision was not due to any disagreement with the company
Dr. DeFord would not have stood for re-election at the June 3, 2026 annual meeting
Chairman David C. Paul thanked him for his work on the NuVasive merger and the Nominating and Governance Committee
SiriusPoint International, a subsidiary of SiriusPoint Ltd., signed a Settlement Agreement with its President and CEO Rob Gibbs on March 17, 2026, in connection with his departure. The severance package is 401,700 GBP, paid in 12 monthly installments after his last day of employment on April 30, 2026, and the company will also cover some medical and life assurance costs into 2027.
Rob Gibbs, President & CEO of SiriusPoint International, is departing; his last day of employment is April 30, 2026.
Severance is 401,700 GBP, paid in 12 equal monthly installments, and includes payment in lieu of his six-month notice period.
Gibbs will not receive a bonus for 2025, and medical coverage is to continue through April 30, 2027.
The settlement includes a general release of claims and ongoing confidentiality, non-compete, and non-solicitation obligations.
Customers Bancorp director Robert N. Mackay told the company on March 20, 2026 that he intends to retire from the boards of the company and Customers Bank and will not stand for reelection at the 2026 Annual Meeting of Shareholders. He cited the increasing demands of his role as CEO of a global regulatory technology company, and the filing states the decision is not related to any disagreement over company or bank operations, policies or practices.
Robert N. Mackay informed the company on March 20, 2026 of his intent to retire and not stand for reelection.
His retirement takes effect immediately after the 2026 Annual Meeting of Shareholders.
Mackay has been a director since 2022 and sits on the Directors Risk & Compliance Committee and the Leadership Development & Compensation Committee.
The filing says the decision is not related to any disagreement on company or bank matters.
Sir Martin Franklin, the company's Executive Chairman, will not seek reelection and will leave the Board at the 2026 annual meeting or by May 4, 2026. The Board is reducing its size from eight to seven directors effective May 4, 2026, and Ian Ashken will become Non-Executive Chairman at the annual meeting. The filing reports no disagreement with the company and no financial results, so the change is governance-related rather than a change in operating performance.
Sir Martin E. Franklin will not seek reelection and will retire from the Board by May 4, 2026
Board size reduced from eight to seven directors, effective May 4, 2026
Ian G.H. Ashken, a founding director since 2013, to become Non-Executive Chairman at the 2026 Annual Meeting
Filing states there was no disagreement between Franklin and the company
Freeport-McMoRan director Robert W. Dudley told the Lead Independent Director and Chairman on March 20, 2026 that he will not seek re-election at the 2026 annual meeting of stockholders. He will serve the rest of his current term, which ends at that meeting, and the company said his decision was not due to any disagreement with the company. The change is a routine board transition that does not affect financial results.
Director Robert W. Dudley informed the Board on March 20, 2026 that he will not stand for re-election
His current term ends at the Company's 2026 annual meeting of stockholders
The company states the decision was not due to any disagreement with the Company
Okta director Jeff Epstein told the company on March 19, 2026 that he will resign from the Board of Directors, effective at the 2026 annual stockholder meeting currently planned for June 18, 2026. The filing says the departure is not the result of any disagreement with the company, and the board thanked him for his service.
Jeff Epstein notified Okta on March 19, 2026 of his board resignation.
Resignation takes effect at the 2026 annual meeting of stockholders, currently planned for June 18, 2026.
The filing states the departure is not due to any disagreement with the company.
Arcus Biosciences said Chief Operating Officer Jennifer Jarrett decided to resign, effective March 30, 2026, and that the resignation is not due to any disagreement with the company on operations, policies or practices. Under a separation agreement, she will provide periodic advisory services through June 30, 2026, and the company extended her post-termination option exercise period to twelve months.
Jennifer Jarrett resigns as Chief Operating Officer, effective March 30, 2026; notice given March 17, 2026
Resignation is stated to be unrelated to any disagreement with the company
Jarrett will provide advisory services through June 30, 2026; vested options exercisable for twelve months after termination
Full separation agreement to be filed with the next Form 10-Q
State Street's board elected Susan Gordon as an independent director on March 19, 2026, and appointed her to the Examining and Audit Committee and the Technology and Operations Committee. She will receive a pro rata share of the $110,000 annual retainer and a $235,000 common stock retainer, under terms consistent with those previously disclosed.
Susan Gordon elected independent director on March 19, 2026
Appointed to Examining and Audit Committee and Technology and Operations Committee
Pro rata share of $110,000 annual retainer and $235,000 common stock retainer; stock award priced at NYSE closing price on election date
Cardinal Health said Gregory B. Kenny is retiring from its board, its committees and the chair role, effective March 20, 2026, and that he is not leaving because of any disagreement with the company. The board appointed director Patricia A. Hemingway Hall as chair, effective immediately. The company also said it will report third quarter fiscal 2026 earnings on April 30, 2026, and remains confident in its fiscal 2026 outlook.
Gregory B. Kenny's retirement from the board and as Board Chair is effective March 20, 2026, and was not due to any disagreement with the company
Patricia A. Hemingway Hall, a director since 2013, was appointed Board Chair effective immediately
Cardinal Health will release third quarter fiscal 2026 earnings on April 30, 2026
The company states it remains confident in its outlook for fiscal 2026
Ingredion disclosed that director Gregory B. Kenny will retire from the Board effective March 23, 2026, after serving since 2005, and that the Board elected Siobhán Talbot as a director effective April 1, 2026. Kenny said his retirement was not due to any disagreement with the Company, and the Board classed Talbot as independent under NYSE standards. The change is a routine board rotation with no reported effect on financial results.
Gregory B. Kenny informed the Company on March 20, 2026 of his decision to retire from the Board, effective March 23, 2026.
Kenny had served as a director since 2005 and said the decision was not due to any disagreement on operations, policies, or practices.
The Board elected Siobhán Talbot as a director on March 18, 2026, with her term beginning April 1, 2026.
Talbot, age 62, is the former Group Managing Director and CEO of Glanbia plc (November 2013 to December 2023) and sits on the CRH plc board.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.